Tunitas Therapeutics, Inc. is a privately held biopharmaceutical company that is developing novel and precisely targeted protein therapeutics with the potential to dramatically change the lives of allergy sufferers. The company's therapeutic approach offers the potential for long-lasting treatments with greater safety and improved efficacy than existing therapies for many serious allergic diseases, such as asthma and food allergy.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/30/15 | $10,000,000 | Series A |
Ally Bridge Group RA Capital WuXi Healthcare Ventures | undisclosed |
